United Nations Development Programme

NANCY BAKER CAHILL & SOPHIA THE ROBOT: STONE SPEAKS

Retrieved on: 
Wednesday, November 30, 2022

MIAMI and DUBAI, UAE, Nov. 30, 2022 /PRNewswire/ -- Borderless Capital is pleased to announce a historic collaboration between the artist Nancy Baker Cahill and Sophia the Robot on a monumental new AR artwork to launch during Art Basel Miami Beach 2022 and the Decipher 2022 Conference in Dubai, November 28 - 30, 2022. The artwork will be listed for sale on Aorist starting Tuesday, November 29, and the sale will close on Sunday, December 4.

Key Points: 
  • STONE SPEAKSis narrative augmented reality (AR) artwork inspired by conversations between artist Nancy Baker Cahill and Sophia the Robot, Hanson Robotics' latest human-like robot, who was first activated in 2016.
  • In the spirit of Baker Cahill's previous monumental AR works, such as Mushroom Cloud and CORPUS, STONE SPEAKS appears overheadas a massive particle field representing the elements silicon and carbon.
  • The 1/1 NFT of this unique Augmented Reality artwork created between Baker Cahill and Sophia, will be available for sale through Aorist starting Tuesday, November 29.
  • Nancy Baker Cahill is an award-winning new media artist who examines systemic power, selfhood, and embodied consciousness through drawing and shared immersive space.

CRDC GLOBAL AND PA CONSULTING - WORKING TOGETHER TO REGENERATE PLASTIC WASTE INTO A CARBON CAPTURE AGGREGATE FOR THE GLOBAL CONSTRUCTION SECTOR

Retrieved on: 
Wednesday, November 30, 2022

LONDON and NEW YORK, Nov. 30, 2022 /PRNewswire/ -- CRDC Global Limited (CRDC Global) , today confirmed that it is actively working with PA Consulting (PA), the global innovation and transformation consultancy that's bringing ingenuity to life, to support the commercialization of its new patent pending RESIN8 Carbon Capture aggregate.

Key Points: 
  • LONDON and NEW YORK, Nov. 30, 2022 /PRNewswire/ -- CRDC Global Limited (CRDC Global) , today confirmed that it is actively working with PA Consulting (PA), the global innovation and transformation consultancy that's bringing ingenuity to life, to support the commercialization of its new patent pending RESIN8 Carbon Capture aggregate.
  • CRDC Global is a disruptive and innovative building materials company that creates appreciating value from the world's plastic waste.
  • CRDC's groundbreaking new technology, RESIN8 Carbon Capture, is a synthetic lightweight aggregate which absorbs CO2 and simulates natural construction sand.
  • Donald Thomson, CEO of CRDC Global, said; "We are an impact driven company with the goal of solving our current plastic waste dilemma while lowering global carbon levels.

CRDC Global and PA Consulting - Working Together to Regenerate Plastic Waste Into a Carbon Capture Aggregate for the Global Construction Sector

Retrieved on: 
Wednesday, November 30, 2022

CRDC Global Limited (CRDC Global), today confirmed that it is actively working with PA Consulting (PA), the global innovation and transformation consultancy thats bringing ingenuity to life, to support the commercialization of its new patent pending RESIN8 Carbon Capture aggregate.

Key Points: 
  • CRDC Global Limited (CRDC Global), today confirmed that it is actively working with PA Consulting (PA), the global innovation and transformation consultancy thats bringing ingenuity to life, to support the commercialization of its new patent pending RESIN8 Carbon Capture aggregate.
  • CRDC Global is a disruptive and innovative building materials company that creates appreciating value from the worlds plastic waste.
  • CRDCs groundbreaking new technology, RESIN8 Carbon Capture, is a synthetic lightweight aggregate which absorbs CO2 and simulates natural construction sand.
  • Donald Thomson, CEO of CRDC Global, said; We are an impact driven company with the goal of solving our current plastic waste dilemma while lowering global carbon levels.

Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases

Retrieved on: 
Wednesday, November 30, 2022

SHANGHAI, China and SEOUL, Republic of Korea, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, and the International Vaccine Institute, an international nonprofit organization devoted to providing vaccines critical to global public health and based in Seoul, Korea, today announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 (CpG 1018/Alum) reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.

Key Points: 
  • Among the 134 household contacts of infected household members who had received SCB-2019, there was one case of COVID-19; among the 250 household contacts of infected household members who were not vaccinated, there were 12 cases.
  • There were no cases of symptomatic SARS-CoV-2 infection among household contacts who were partially or fully vaccinated and where the infected household member was vaccinated with SCB-2019.
  • This indicates that SCB-2019 vaccination reduced household transmission and that vaccinated household contacts also likely benefited from the protection provided by their own vaccination.
  • The study team was blinded to the assignment of SPECTRA participants to vaccine or placebo groups.

CEO & Founder of TriLinc Global Gloria Nelund Joins AI for the Planet Advisory Board: A New Alliance to Help Artificial Intelligence (AI) Achieve Its Potential to Support Climate Change Efforts at Scale

Retrieved on: 
Monday, November 14, 2022

We are excited to be a part of this new global alliance which will help AI achieve its potential to support climate change efforts at scale as well as establish a global platform to identify the top uses of AI in addressing climate change, stated Ms. Nelund.

Key Points: 
  • We are excited to be a part of this new global alliance which will help AI achieve its potential to support climate change efforts at scale as well as establish a global platform to identify the top uses of AI in addressing climate change, stated Ms. Nelund.
  • Climate change causes, and will continue to cause, major impacts on environmental, social, and economic systems around the globe.
  • Mitigation efforts, including achieving net zero emissions by 2050 are needed to limit global temperature rise and its repercussions.
  • AI for the Planet will build a multidisciplinary and diverse coalition of AI and climate leaders to drive concrete and measurable action.

Artificial Intelligence As A Service Market Worth $96,064.7 Million By 2030: Grand View Research, Inc.

Retrieved on: 
Monday, November 21, 2022

Artificial intelligence as a service (AIaaS) is a third-party artificial intelligence outsourcing service that allows large enterprises and SMEs to explore development opportunities without requiring a significant initial investment.

Key Points: 
  • Artificial intelligence as a service (AIaaS) is a third-party artificial intelligence outsourcing service that allows large enterprises and SMEs to explore development opportunities without requiring a significant initial investment.
  • The increased usage of cloud-based solutions and the need for artificial intelligence and cognitive computing drive market expansion.
  • Read 100-page full market research report, " Artificial Intelligence As A Service Market Size, Share & Trends Analysis Report By Technology, By Service Type, By Deployment, By Vertical (BFSI, Healthcare, Retail, Energy & Utility), By Region, And Segment Forecasts, 2022 - 2030 ", published by Grand View Research.
  • Grand View Research has segmented the global artificial intelligence as a service (AIaaS) market based on technology, service type, organizations size, deployment, vertical, and region
    Artificial Intelligence As A ServiceMarket - Technology Outlook (Revenue, USD Million, 2017 - 2030)

Artificial Intelligence As A Service Market Worth $96,064.7 Million By 2030: Grand View Research, Inc.

Retrieved on: 
Monday, November 21, 2022

Artificial intelligence as a service (AIaaS) is a third-party artificial intelligence outsourcing service that allows large enterprises and SMEs to explore development opportunities without requiring a significant initial investment.

Key Points: 
  • Artificial intelligence as a service (AIaaS) is a third-party artificial intelligence outsourcing service that allows large enterprises and SMEs to explore development opportunities without requiring a significant initial investment.
  • The increased usage of cloud-based solutions and the need for artificial intelligence and cognitive computing drive market expansion.
  • Read 100-page full market research report, " Artificial Intelligence As A Service Market Size, Share & Trends Analysis Report By Technology, By Service Type, By Deployment, By Vertical (BFSI, Healthcare, Retail, Energy & Utility), By Region, And Segment Forecasts, 2022 - 2030 ", published by Grand View Research.
  • Grand View Research has segmented the global artificial intelligence as a service (AIaaS) market based on technology, service type, organizations size, deployment, vertical, and region
    Artificial Intelligence As A ServiceMarket - Technology Outlook (Revenue, USD Million, 2017 - 2030)

Yili Participated in the COP27 Panel Discussion on Green Business Practices

Retrieved on: 
Monday, November 14, 2022

Representatives of international organizations and enterprises joinedroundtable discussions on the respective "Green Practices of Businesses andOpportunities on Renewable Energy Supply Chain" panels.

Key Points: 
  • Representatives of international organizations and enterprises joinedroundtable discussions on the respective "Green Practices of Businesses andOpportunities on Renewable Energy Supply Chain" panels.
  • Yili was invited to attend the seminar online as a representative from China'sfood product industry.
  • Pan Gang, Chairman and President of Yili Group, initially proposeda concept of "Green Leadership" in 2007 and introduced the "Green IndustryChain" in China's dairy business in 2009.
  • Yili promotes green manufacturing in its plants by enhancing energyefficiency, utilizing renewable energy, and employing environmentally friendlypackaging.

GHIT Fund Announces New Investments: A Total of 790 Million Yen for Product Development of Neglected Tropical Diseases

Retrieved on: 
Friday, November 11, 2022

TOKYO, Nov. 10, 2022 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total of approximately 790 million yen (US$5.3 million*) to invest in product development for lymphatic filariasis and onchocerciasis, two neglected tropical diseases (NTDs).

Key Points: 
  • TOKYO, Nov. 10, 2022 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total of approximately 790 million yen (US$5.3 million*) to invest in product development for lymphatic filariasis and onchocerciasis, two neglected tropical diseases (NTDs).
  • Neglected tropical diseases caused by parasitic infection: New drug development for lymphatic filariasis and onchocerciasis
    Lymphatic filariasis (elephantiasis) and onchocerciasis (river blindness) are two neglected tropical diseases that are caused by parasitic worms.
  • The GHIT Fund invests and manages an R&D portfolio of development partnerships aimed at neglected diseases, such as malaria, tuberculosis and neglected tropical diseases that afflict the world's vulnerable and underserved populations.
  • The GHIT Fund mobilizes the Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases, in collaboration with global partners.

Lemonex, IVI Exchange MOU on Joint Vaccine Development

Retrieved on: 
Thursday, November 10, 2022

The International Vaccine Institute (IVI) announced on November 10th it signed a memorandum of understanding (MOU) with Lemonex, a company specializing in RNA gene therapy development, and agreed to seek cooperation in research and development.

Key Points: 
  • The International Vaccine Institute (IVI) announced on November 10th it signed a memorandum of understanding (MOU) with Lemonex, a company specializing in RNA gene therapy development, and agreed to seek cooperation in research and development.
  • IVI and Lemonex have agreed to join forces to introduce DegradaBALL drug delivery technology to the development of infectious disease vaccines and advance vaccine development by using IVIs extensive expertise in all areas of vaccine development.
  • The two organizations plan to utilize Lemonex's expertise in vaccine development and drug delivery platform, and rapidly develop a safe and effective mRNA vaccine through mutual cooperation by using IVI's extensive experience in clinical development and epidemiology.
  • Cheolhee Won, CEO of Lemonex, said, We are proud to have established a vaccine R&D partnership with IVI to develop an mRNA vaccine.